Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 910

-SubTopic 310

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6471494&loc=d3e49354-109356

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph c

-Article 5

Name:	us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) (USD $) In Millions, unless otherwise specified			12 Months Ended			1 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 United States, Europe, Japan and Other Countries [Member] GSK	Jun. 30, 2014 Australia, New Zealand, South Africa and Indonesia GSK	Jun. 30, 2014 Japan [Member] Daiichi Sankyo	Mar. 31, 2011 BARDA	Jun. 30, 2014 BARDA
Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage			7.00%	10.00%	4.00%
Maximum Revenue from Contract						$ 231.2
Contract Term						5 years
Contract Receivable	17.8	10.9					17.8
Contracts Receivable, Claims and Uncertain Amounts						$ 3.7